

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>IMAGION BIOSYSTEMS LIMITED</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert <b>PROULX</b>
<b>Date of last notice</b>	11 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	22 October 2020
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>i) 3,487,000 Shares</li> <li>ii) 7,500,000 Performance Rights</li> <li>iii) 176,250 Listed Options (exercisable at \$0.05 expiring on 26 November 2021)</li> <li>iv) 282,000 Listed Options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>v) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>vi) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> <li>vii) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)</li> </ul>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	<ul style="list-style-type: none"> <li>i) Fully Paid Ordinary Shares (<b>Shares</b>)</li> <li>ii) Performance Rights</li> <li>iii) Listed Options (exercisable at \$0.05 expiring on 26 November 2021)</li> <li>iv) Listed Options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>v) Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>vi) Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> <li>vii) Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)</li> </ul>
<b>Number acquired</b>	<ul style="list-style-type: none"> <li>i) 2,500,000 Shares</li> <li>ii) Nil Performance Rights</li> <li>iii) Nil Listed Options (exercisable at \$0.05 expiring on 26 November 2021)</li> <li>iv) Nil Listed Options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>v) Nil Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>vi) Nil Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> <li>vii) Nil Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)</li> </ul>
<b>Number disposed</b>	2,500,000 Performance Rights

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	i) Nil per Share ii) N/A Consideration for Performance Rights iii) N/A consideration for Listed Options (exercisable at \$0.05 expiring on 26 November 2021) iv) N/A Consideration for Listed Options (exercisable at \$0.03, expiring on 28 April 2023) v) N/A Consideration for Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) vi) N/A Consideration for Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027) vii) N/A Consideration for Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)
<b>No. of securities held after change</b>	i) 5,987,000 Shares ii) 5,000,000 Performance Rights iii) 176,250 Listed Options (exercisable at \$0.05 expiring on 26 November 2021) iv) 282,000 Listed Options (exercisable at \$0.03, expiring on 28 April 2023) v) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) vi) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027) vii) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares were issued as the result of vesting of Performance Rights.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

For personal use only